Review of treatments for generalized pustular psoriasis

References

• Benjegerdes KE, Hyde K, Kivelevitch D, et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–144.
   PubMed Web of Science ®Google Scholar
• Kawada A, Tezuka T, Nakamizo Y, et al. Japanese Society for Psoriasis, A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci. 2003;31(1):59–64.
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–628.
   PubMed Web of Science ®Google Scholar
• Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–288.
   PubMed Web of Science ®Google Scholar
• Booij MT, Van De Kerkhof PC. Acitretin revisited in the era of biologics. J Dermatolog Treat. 2011;22(2):86–89.
   PubMed Web of Science ®Google Scholar
• Ozawa A, Ohkido M, Haruki Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol. 1999;26(3):141–149.
   PubMedGoogle Scholar
• Olsen EA, Weed WW, Meyer CJ, et al. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol. 1989;21(4):681–686.
   PubMed Web of Science ®Google Scholar
• Mengesha YM, Bennett ML. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol. 2002;3(6):389–400.
   PubMedGoogle Scholar
• Meinardi MM, Westerhof W, Bos JD. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol. 1987;116(2):269–270.
   PubMed Web of Science ®Google Scholar
• Weishaupt C, Metze D, Luger TA, et al. Treatment of pustular psoriasis with infliximab. J Dtsch Dermatol Ges. 2007;5(5):397–399.
   PubMedGoogle Scholar
• Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venerol. 2000;14(5):382–388.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60(5):824–837.
   PubMed Web of Science ®Google Scholar
• Kilic SS, Hacimustafaoglu M, Celebi S, et al. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001;18(3):246–248.
   PubMed Web of Science ®Google Scholar
• Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol. 2002;41(7):449–452.
   PubMed Web of Science ®Google Scholar
• Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9(1):1–14.
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092–1102.
   PubMed Web of Science ®Google Scholar
• Bohner A, Roenneberg S, Eyerich K, et al. Acute generalized pustular psoriasis treated with the IL-17A antibody secukinumab. JAMA Dermatol. 2016;152(4):482–484.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, Japanese Ixekizumab Study, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362.
   PubMed Web of Science ®Google Scholar
• Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178(5):1003–1005.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, Japanese Brodalumab Study, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741–751.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–181.
   PubMed Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539.
   PubMed Web of Science ®Google Scholar
• Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016;152(7):825–828.
   PubMed Web of Science ®Google Scholar
• Storan ER, O'Gorman SM, Markham T. Generalized pustular psoriasis treated with ustekinumab. Clin Exp Dermatol. 2016;41(6):689–690.
   PubMed Web of Science ®Google Scholar
• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981–983.
   PubMed Web of Science ®Google Scholar
• Skendros P, Papagoras C, Lefaki I, et al. Successful response in a case of severe pustular psoriasis after interleukin-1beta inhibition. Br J Dermatol. 2017;176(1):212–215.
   PubMed Web of Science ®Google Scholar
• Mansouri B, Kivelevitch D, Campa M, et al. Palmoplantar pustular psoriasis unresponsive to the interleukin-1beta antagonist canakinumab. Clin Exp Dermatol. 2016;41(3):324–326.
   PubMed Web of Science ®Google Scholar